back to cluster viewer
cluster path 000111111100
58 words, 6,986 tokens
freq alpha suffix
Words in frequency order
1 | implications | 6,797
|
2 | ramifications | 118
|
3 | candidature | 5
|
4 | blueprints | 3
|
5 | cmaxs | 3
|
6 | languished | 3
|
7 | summations | 3
|
8 | sglt2-inhibitors | 2
|
9 | test-case | 2
|
10 | web-servers | 2
|
11 | -schooling | 1
|
12 | 3-alkoxyfurans | 1
|
13 | 7mg/m²week | 1
|
14 | antimicrobiotics | 1
|
15 | areas-under-the-curve | 1
|
16 | boht | 1
|
17 | c-source | 1
|
18 | conclusion/implication | 1
|
19 | de-training | 1
|
20 | delthv/sv | 1
|
21 | differences.in | 1
|
22 | dose/cnr | 1
|
23 | double-immunostaining | 1
|
24 | ecg-recordings | 1
|
25 | equivations | 1
|
26 | fosfomycin/tobramycin | 1
|
27 | guideposts | 1
|
28 | immunoprophyloxis | 1
|
29 | injection/week | 1
|
30 | inmunoregulatory | 1
|
31 | isrctn11916376 | 1
|
32 | japiccti-121902 | 1
|
33 | membrane-resident | 1
|
34 | mifipristone | 1
|
35 | nct01381549 | 1
|
36 | nct01381562 | 1
|
37 | neonatal-requirement | 1
|
38 | non-uniqueness | 1
|
39 | nonheterogeneity | 1
|
40 | overdistensiblity | 1
|
41 | pathomarker | 1
|
42 | photoacceptor | 1
|
43 | phyto-constituents | 1
|
44 | predeterminant | 1
|
45 | prosecutions | 1
|
46 | pscbs | 1
|
47 | pupil-factors | 1
|
48 | refloats | 1
|
49 | reserve-antibiotics | 1
|
50 | situations.in | 1
|
51 | spectro-microscope | 1
|
52 | starch-fractions | 1
|
53 | tablerisk | 1
|
54 | targets/pathways | 1
|
55 | tip1 | 1
|
56 | top1-3 | 1
|
57 | trial-justification | 1
|
58 | xelox-bevacizumab | 1
|
Words in alphabetical order
1 | -schooling | 1
|
2 | 3-alkoxyfurans | 1
|
3 | 7mg/m²week | 1
|
4 | antimicrobiotics | 1
|
5 | areas-under-the-curve | 1
|
6 | blueprints | 3
|
7 | boht | 1
|
8 | c-source | 1
|
9 | candidature | 5
|
10 | cmaxs | 3
|
11 | conclusion/implication | 1
|
12 | de-training | 1
|
13 | delthv/sv | 1
|
14 | differences.in | 1
|
15 | dose/cnr | 1
|
16 | double-immunostaining | 1
|
17 | ecg-recordings | 1
|
18 | equivations | 1
|
19 | fosfomycin/tobramycin | 1
|
20 | guideposts | 1
|
21 | immunoprophyloxis | 1
|
22 | implications | 6,797
|
23 | injection/week | 1
|
24 | inmunoregulatory | 1
|
25 | isrctn11916376 | 1
|
26 | japiccti-121902 | 1
|
27 | languished | 3
|
28 | membrane-resident | 1
|
29 | mifipristone | 1
|
30 | nct01381549 | 1
|
31 | nct01381562 | 1
|
32 | neonatal-requirement | 1
|
33 | non-uniqueness | 1
|
34 | nonheterogeneity | 1
|
35 | overdistensiblity | 1
|
36 | pathomarker | 1
|
37 | photoacceptor | 1
|
38 | phyto-constituents | 1
|
39 | predeterminant | 1
|
40 | prosecutions | 1
|
41 | pscbs | 1
|
42 | pupil-factors | 1
|
43 | ramifications | 118
|
44 | refloats | 1
|
45 | reserve-antibiotics | 1
|
46 | sglt2-inhibitors | 2
|
47 | situations.in | 1
|
48 | spectro-microscope | 1
|
49 | starch-fractions | 1
|
50 | summations | 3
|
51 | tablerisk | 1
|
52 | targets/pathways | 1
|
53 | test-case | 2
|
54 | tip1 | 1
|
55 | top1-3 | 1
|
56 | trial-justification | 1
|
57 | web-servers | 2
|
58 | xelox-bevacizumab | 1
|
Words in suffix order
1 | tip1 | 1
|
2 | japiccti-121902 | 1
|
3 | nct01381562 | 1
|
4 | top1-3 | 1
|
5 | isrctn11916376 | 1
|
6 | nct01381549 | 1
|
7 | xelox-bevacizumab | 1
|
8 | languished | 3
|
9 | c-source | 1
|
10 | mifipristone | 1
|
11 | spectro-microscope | 1
|
12 | candidature | 5
|
13 | test-case | 2
|
14 | areas-under-the-curve | 1
|
15 | -schooling | 1
|
16 | de-training | 1
|
17 | double-immunostaining | 1
|
18 | injection/week | 1
|
19 | 7mg/m²week | 1
|
20 | tablerisk | 1
|
21 | differences.in | 1
|
22 | situations.in | 1
|
23 | fosfomycin/tobramycin | 1
|
24 | trial-justification | 1
|
25 | conclusion/implication | 1
|
26 | pathomarker | 1
|
27 | dose/cnr | 1
|
28 | photoacceptor | 1
|
29 | pscbs | 1
|
30 | reserve-antibiotics | 1
|
31 | antimicrobiotics | 1
|
32 | ecg-recordings | 1
|
33 | immunoprophyloxis | 1
|
34 | 3-alkoxyfurans | 1
|
35 | ramifications | 118
|
36 | implications | 6,797
|
37 | summations | 3
|
38 | equivations | 1
|
39 | starch-fractions | 1
|
40 | prosecutions | 1
|
41 | web-servers | 2
|
42 | pupil-factors | 1
|
43 | sglt2-inhibitors | 2
|
44 | non-uniqueness | 1
|
45 | refloats | 1
|
46 | phyto-constituents | 1
|
47 | blueprints | 3
|
48 | guideposts | 1
|
49 | cmaxs | 3
|
50 | targets/pathways | 1
|
51 | boht | 1
|
52 | predeterminant | 1
|
53 | membrane-resident | 1
|
54 | neonatal-requirement | 1
|
55 | delthv/sv | 1
|
56 | inmunoregulatory | 1
|
57 | nonheterogeneity | 1
|
58 | overdistensiblity | 1
|